NVNO

enVVeno Medical Corporation (NVNO) | Rumor.io

enVVeno Medical

NVNO

Attention (50-day avg)0%

Attention rank (50-day avg)#3,905

Bullish sentiment (50-day avg)0%

Price to earnings ratio-0.26

Market capitalization6.1M

Earnings per share-25

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-19.5M

Social

What share of all stock conversation is about NVNO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 29

enVVeno Medical Corporation (NVNO) received FDA IDE approval for a US pivotal study of a non-surgical replacement venous valve.
The approval addresses a significant market need, as 3 million Americans suffer from severe chronic venous insufficiency, with no effective treatment available.
The company's stock price has increased by 0.39% to $13.00, with some investors expressing bullish sentiment, while others are cautious due to the company's low float and lack of institutional investor interest.

Generated by AI

Sentiment

Of the messages about NVNO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% 0	85.28% +5.37
Bearish	—	—	100% 0	14.72% -5.37

Bullish· Jan 30

$NVNO breaks key resistance at $10.93, projecting a 24.05% surge to $16.32, with reverse split news acting as a structural catalyst.
Institutional accumulation confirmed by high volume, with $NVNO decisively breaching $10.78 resistance on a 20.18% surge, targeting $15.30.
$NVNO surges to $12.20 +21.88% on a reverse stock split, accelerating user growth and signaling a high-conviction, high-risk momentum play.

Bearish· Aug 21

The company's management team has been proven incompetent, and the stock is now a massive dilution hopium bet.
The company will need substantial funding for remaining trials and commercialization, which is unlikely given the current cash balance and VenoValve profits.
The stock price will likely fall to $0.40-$0.50, and those who hold on will regret not taking gains earlier or decreasing their potential losses.

Generated by AI

Topics

Of the messages about NVNO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	52.17%
Analysts	—	—	0%	20.29%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	16.91%
Technical Analysis	—	—	0%	10.63%

Announcements· Aug 20

The FDA issued a "not-approvable" letter for enVVeno Medical Corporation's VenoValve PMA, citing insufficient evidence of benefit-risk despite improvements in clinical scores and raising safety concerns tied to the surgical procedure.
The company is evaluating options, including a potential appeal or resubmission, while continuing development of its non-surgical venous valve, enVVe.
The FDA flagged safety risks from the open-surgery procedure, noting several rehospitalizations, and questioned whether patient improvements were due to the device or study participation.

Technical Analysis· Jan 30

$NVNO decisively breaches key resistance at $10.85, with high-volume surge confirming institutional momentum and a technical target of $15.74.
The reverse split news acts as a structural catalyst for the move, with volume confirming the technical breakout and targeting $15.30.
$NVNO breaks key resistance at $10.93 on elevated volume, with a technical target of $16.32 following a +24.05% surge and the reverse split news providing a structural catalyst for momentum.

Generated by AI

Community

Of the messages about NVNO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	42.86%	16.67%
Newcomers	—	—	57.14%	83.33%

Feb 20

The newcomer is excited about enVVeno Medical Corporation's ($NVNO) recent $6.5M private placement, seeing it as a significant influx of cash.
The float is relatively small at 577K, and the newcomer notes that RS is scheduled to be priced in January, implying a possible IPO in the near future.
Perceptive Advisory, a notable investor, owns a significant 9.9% stake in the company, according to the most recent filing on February 26.

Generated by AI

New CEO-led video series provides investors with straight talk, just the facts, with no B. or corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch the inaugural episode hereIRVINE, CA / ACCESS Newswire / September 16, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the launch of "WTF Rob Berman" a new video series that provides the information that investors need to know, in straight talk, with no corporate spin.

13d agoYahoo Finance

Enveno medical director Francis Duhay sells $123 in shares

15d agoInvesting.com

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

Access the video webcast hereIRVINE, CA / ACCESS Newswire / September 11, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded presentation from the H. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.

19d agoYahoo Finance

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

IRVINE, CA/ ACCESS Newswire/ August 27, 2026/ enVVeno Medical Corporation today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, participated in the Virtual Investor "Why Now" on-demand conference. JTC Team and Virtual Investor Co. are paid consultants to enVVeno Medical Corporation. Any content included in this release shall not be...

1mo agoNasdaq

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be used to support future coverage ...

1mo agoYahoo Finance

enVVeno Medical receives FDA approval for pivotal trial

2mo agoInvesting.com

Also Discussed

Investors talking about NVNO also mention

#	Name	Attention
1	TFFP - TFF Pharmaceuticals, Inc.	——
2	CN Energy Group Inc. Class A Ordinary SharesCNEY	0%new
3	INmune Bio Inc.INMB	0%0
4	Innovation Beverage Group LimitedIBG	0%new
5	Emerson Radio Corp.MSN	0%0
6	WHLM - Wilhelmina International, Inc.	——
7	Perma-Fix Environmental Services, Inc.PESI	0%0
8	Martin Midstream Partners L.P.MMLP	0%new
9	Ambow Education Holding Ltd. ADRAMBO	0%0
10	Quest Resource Holding Corp.QRHC	0%new

enVVeno Medical Corporation

Healthcare
Medical Devices

enVVeno Medical Corporation is a medical device company focused on developing bioprosthetic, tissue-based solutions for venous disease. The company’s current portfolio centers on the VenoValve, a surgical replacement venous valve designed for patients with deep venous chronic venous insufficiency, and enVVe, a non-surgical, transcatheter-based venous valve system under development. These products are intended to address valve failure in the deep venous system and support more effective blood flow in patients with chronic venous disorders. enVVeno Medical Corporation serves the broader vascular medicine market, where it aims to improve treatment options for conditions that can cause pain, swelling, and long-term circulatory problems. Based in Irvine, California and incorporated in 1999, the company remains a late clinical-stage player in specialized medical technology, with a business model centered on advancing implantable and minimally invasive venous care solutions.

Website

Location

70 Doppler

Irvine, CA, 92618

United States

Social

What share of all stock conversation is about NVNO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Apr 29

enVVeno Medical Corporation (NVNO) received FDA IDE approval for a US pivotal study of a non-surgical replacement venous valve.
The approval addresses a significant market need, as 3 million Americans suffer from severe chronic venous insufficiency, with no effective treatment available.
The company's stock price has increased by 0.39% to $13.00, with some investors expressing bullish sentiment, while others are cautious due to the company's low float and lack of institutional investor interest.

Generated by AI

Sentiment

Of the messages about NVNO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% 0	85.28% +5.37
Bearish	—	—	100% 0	14.72% -5.37

Bullish· Jan 30

$NVNO breaks key resistance at $10.93, projecting a 24.05% surge to $16.32, with reverse split news acting as a structural catalyst.
Institutional accumulation confirmed by high volume, with $NVNO decisively breaching $10.78 resistance on a 20.18% surge, targeting $15.30.
$NVNO surges to $12.20 +21.88% on a reverse stock split, accelerating user growth and signaling a high-conviction, high-risk momentum play.

Bearish· Aug 21

The company's management team has been proven incompetent, and the stock is now a massive dilution hopium bet.
The company will need substantial funding for remaining trials and commercialization, which is unlikely given the current cash balance and VenoValve profits.
The stock price will likely fall to $0.40-$0.50, and those who hold on will regret not taking gains earlier or decreasing their potential losses.

Generated by AI

Topics

Of the messages about NVNO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	52.17%
Analysts	—	—	0%	20.29%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	16.91%
Technical Analysis	—	—	0%	10.63%

Announcements· Aug 20

The FDA issued a "not-approvable" letter for enVVeno Medical Corporation's VenoValve PMA, citing insufficient evidence of benefit-risk despite improvements in clinical scores and raising safety concerns tied to the surgical procedure.
The company is evaluating options, including a potential appeal or resubmission, while continuing development of its non-surgical venous valve, enVVe.
The FDA flagged safety risks from the open-surgery procedure, noting several rehospitalizations, and questioned whether patient improvements were due to the device or study participation.

Technical Analysis· Jan 30

$NVNO decisively breaches key resistance at $10.85, with high-volume surge confirming institutional momentum and a technical target of $15.74.
The reverse split news acts as a structural catalyst for the move, with volume confirming the technical breakout and targeting $15.30.
$NVNO breaks key resistance at $10.93 on elevated volume, with a technical target of $16.32 following a +24.05% surge and the reverse split news providing a structural catalyst for momentum.

Generated by AI

Community

Of the messages about NVNO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	42.86%	16.67%
Newcomers	—	—	57.14%	83.33%

Feb 20

The newcomer is excited about enVVeno Medical Corporation's ($NVNO) recent $6.5M private placement, seeing it as a significant influx of cash.
The float is relatively small at 577K, and the newcomer notes that RS is scheduled to be priced in January, implying a possible IPO in the near future.
Perceptive Advisory, a notable investor, owns a significant 9.9% stake in the company, according to the most recent filing on February 26.

Generated by AI

enVVeno Medical

Social

Apr 29

Sentiment

Bullish· Jan 30

Bearish· Aug 21

Topics

Announcements· Aug 20

Technical Analysis· Jan 30

Community

Feb 20

News

enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

Enveno medical director Francis Duhay sells $123 in shares

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

enVVeno Medical receives FDA approval for pivotal trial

Also Discussed

enVVeno Medical Corporation

Company Information

Location

News

enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

Enveno medical director Francis Duhay sells $123 in shares

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

enVVeno Medical receives FDA approval for pivotal trial

Also Discussed

Social

Apr 29

Sentiment

Bullish· Jan 30

Bearish· Aug 21

Topics

Announcements· Aug 20

Technical Analysis· Jan 30

Community

Feb 20